BR112023024853A2 - Forma cristalina de (s,e)-4-(dimetilamino)-n-(3-(4-(2-hidroxi-1- base livre de feniletilamino)-6-fenilfuro[2,3-d]pirimidin-5-il)fenil)but-2-enamida (abt-101), composição farmacêutica e método de tratamento de câncer - Google Patents

Forma cristalina de (s,e)-4-(dimetilamino)-n-(3-(4-(2-hidroxi-1- base livre de feniletilamino)-6-fenilfuro[2,3-d]pirimidin-5-il)fenil)but-2-enamida (abt-101), composição farmacêutica e método de tratamento de câncer

Info

Publication number
BR112023024853A2
BR112023024853A2 BR112023024853A BR112023024853A BR112023024853A2 BR 112023024853 A2 BR112023024853 A2 BR 112023024853A2 BR 112023024853 A BR112023024853 A BR 112023024853A BR 112023024853 A BR112023024853 A BR 112023024853A BR 112023024853 A2 BR112023024853 A2 BR 112023024853A2
Authority
BR
Brazil
Prior art keywords
abt
free base
phenylethylamino
enamide
pyrimidin
Prior art date
Application number
BR112023024853A
Other languages
English (en)
Portuguese (pt)
Inventor
Hsing-Pang Hsieh
Sue-Ming Chang
Tsu-An Hsu
Original Assignee
Chuan Shih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chuan Shih filed Critical Chuan Shih
Publication of BR112023024853A2 publication Critical patent/BR112023024853A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112023024853A 2021-07-06 2022-07-06 Forma cristalina de (s,e)-4-(dimetilamino)-n-(3-(4-(2-hidroxi-1- base livre de feniletilamino)-6-fenilfuro[2,3-d]pirimidin-5-il)fenil)but-2-enamida (abt-101), composição farmacêutica e método de tratamento de câncer BR112023024853A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163218504P 2021-07-06 2021-07-06
PCT/US2022/036260 WO2023283269A1 (en) 2021-07-06 2022-07-06 Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base

Publications (1)

Publication Number Publication Date
BR112023024853A2 true BR112023024853A2 (pt) 2024-02-15

Family

ID=84802010

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024853A BR112023024853A2 (pt) 2021-07-06 2022-07-06 Forma cristalina de (s,e)-4-(dimetilamino)-n-(3-(4-(2-hidroxi-1- base livre de feniletilamino)-6-fenilfuro[2,3-d]pirimidin-5-il)fenil)but-2-enamida (abt-101), composição farmacêutica e método de tratamento de câncer

Country Status (12)

Country Link
US (2) US12240858B2 (cg-RX-API-DMAC7.html)
EP (1) EP4330259A4 (cg-RX-API-DMAC7.html)
JP (1) JP7565118B2 (cg-RX-API-DMAC7.html)
KR (1) KR102783648B1 (cg-RX-API-DMAC7.html)
CN (1) CN116916922B (cg-RX-API-DMAC7.html)
AU (1) AU2022307875B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023024853A2 (cg-RX-API-DMAC7.html)
CA (1) CA3217088A1 (cg-RX-API-DMAC7.html)
IL (1) IL308946B2 (cg-RX-API-DMAC7.html)
MX (1) MX2023013093A (cg-RX-API-DMAC7.html)
TW (1) TWI809967B (cg-RX-API-DMAC7.html)
WO (1) WO2023283269A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI906763B (zh) * 2024-02-05 2025-12-01 財團法人國家衛生研究院 表皮生長因子受體抑制劑

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010054285A2 (en) * 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
KR101301533B1 (ko) * 2010-02-09 2013-09-04 한미사이언스 주식회사 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체

Also Published As

Publication number Publication date
MX2023013093A (es) 2024-04-09
TW202309041A (zh) 2023-03-01
IL308946A (en) 2024-01-01
AU2022307875A1 (en) 2023-11-02
CN116916922A (zh) 2023-10-20
IL308946B2 (en) 2026-01-01
JP2024514995A (ja) 2024-04-04
IL308946B1 (en) 2025-09-01
CA3217088A1 (en) 2023-01-12
KR102783648B1 (ko) 2025-03-18
US20230021909A1 (en) 2023-01-26
US20240368175A1 (en) 2024-11-07
WO2023283269A1 (en) 2023-01-12
CN116916922B (zh) 2026-01-02
JP7565118B2 (ja) 2024-10-10
US12240858B2 (en) 2025-03-04
AU2022307875B2 (en) 2024-08-01
KR20230118963A (ko) 2023-08-14
TWI809967B (zh) 2023-07-21
EP4330259A4 (en) 2024-10-09
EP4330259A1 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
BR112018010879A2 (pt) inibidores da proteína quinase, método de preparação e uso médico dos mesmos
EP4467549A3 (en) Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
BRPI0519774A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, formulaÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, mÉtodo de tratamento de uma doenÇa em que inibiÇço da atividade de um membro da famÍlia mapeg É desejada e/ou necessÁria, produto combinado, e, processo para a preparaÇço de um composto
MX2023006854A (es) Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma.
MY167423A (en) Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use
BRPI0514288A (pt) benzamidas substituìdas com triflúor-metila como inibidores de cinases
CN110036005A (zh) 酰胺衍生物及其在药物中的应用
CN111902417A (zh) 一种二芳基巨环化合物、药物组合物以及其用途
BR112022009705A2 (pt) Forma cristalina anidra de um derivado de ácido 7h-benzo[7]anuleno-2-carboxílico, seus usos e processos de preparação, forma sólida, medicamento e composição farmacêutica
RU2015117647A (ru) Новые производные пиразола
RU2017145930A (ru) МОДУЛЯТОРЫ ROR ГАММА (RORγ)
JPWO2020095971A5 (cg-RX-API-DMAC7.html)
BR112023025841A2 (pt) Forma cristalina de tolebrutinibe, método de preparação para mesma e uso da mesma
BR112022008000A2 (pt) Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo
JP2022539152A5 (cg-RX-API-DMAC7.html)
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
WO2013178581A1 (en) Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
BR112022000523A2 (pt) Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica
CA2526989A1 (en) Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
JPWO2020175629A5 (cg-RX-API-DMAC7.html)
JP2021510168A5 (cg-RX-API-DMAC7.html)
AU2008203743B2 (en) Thioxanthene derivates useful to treat infectious diseases
KR20230058615A (ko) 파킨슨병의 운동 합병증 치료약
MX2023013093A (es) Formas cristalinas de la base libre de (s,e)-4-(dimetilamino)-n-(3 -(4-(2-hidroxi-1-feniletilamino)-6-fenilfuro[2,3-d]pirimidin-5-il )fenil)but-2-enamida.